A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998-2004)

A. Pár, István Tornai, F. Szalay

Research output: Article

9 Citations (Scopus)

Abstract

Introduction: In the past decade several multicentre, prospective, randomised trials revealed a significant progress in the therapy for chronic viral hepatitis, but limited and controversal data are available regarding the real value of the antiviral treatment in the everyday routine clinical praxis. Aim: A nation-wide retrospective analysis has been made of the antiviral therapy for patients with hepatitis B and C, who represented the entire patient population necessitating treatment in Hungary during a seven-year period. In addition, results of a prospective study for chronic hepatitis C patients were also presented. Patients and methods: A total of 220 patients with chronic hepatitis B treated with standard interferon α (112), pegylated interferon α 2a (23), or lamivudine (85) were investigated and assessed for the HBeAg seroconversion and/or undetectable HBV-DNA. Out of 2442 chronic hepatitits C patients, 333 were treated with standard interferon monotherapy, 1122 with standard interferon + ribavirin and 987 with pegilated interferon plus ribavirin combination for 6-12 months. In a prospective study, 69 patients with chronic hepatitis C were enrolled and treated with pegilated interferon α-2a plus ribavirin. The rate of sustained virological response, the predictors of outcome and the adverse effects of treatment were evaluated. Results: For HBV patients standard IFN provided 31%, PEG-IFN 30% and lamivudine 31-33% sustained virological response rate, respectively. In chronic hepatitis C, a continuous improvement was noted in sustained virological response, from 13% by interferon monotherapy, to 31% by pegilated interferon plus ribavirin combination, in the nation-wide retrospective study, while even a 48% sustained virological response was achieved in the prospective trial. The most important predictors of outcome were the 4-week "rapid" and the 12-week "early" virological responses, then the female sex, age, BMI and adherence. The most frequent complications of the antiviral treatment were cytopenias, haemolysis and depression, 9% of patients experienced adverse effects. Conclusion: The efficacy of antiviral treatment unlike HBV infection, in chronic HCV hepatitis gradually improved in our every-day clinical praxis, but the results are far poorer than those achieved in a prospective study. To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimized, individualized dosing and novel antivirals.

Original languageHungarian
Pages (from-to)819-826
Number of pages8
JournalOrvosi Hetilap
Volume148
Issue number18
DOIs
Publication statusPublished - máj. 6 2007

Fingerprint

Hungary
Chronic Hepatitis B
Chronic Hepatitis C
Antiviral Agents
Interferons
Ribavirin
Chronic Hepatitis
Therapeutics
Lamivudine
Prospective Studies
Hepatitis B e Antigens
Hepatitis C
Hemolysis
Hepatitis B
Population
Retrospective Studies

Keywords

  • Antiviral treatment
  • Chronic viral hepatitis
  • HBV
  • HCV
  • National survey
  • Prospective study

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998-2004). / Pár, A.; Tornai, István; Szalay, F.

In: Orvosi Hetilap, Vol. 148, No. 18, 06.05.2007, p. 819-826.

Research output: Article

@article{203170f54ab54c86a2ac0a166bee245d,
title = "A kr{\'o}nikus B- {\'e}s C-v{\'i}rushepatitis antivir{\'a}lis kezel{\'e}s{\'e}nek hazai tapasztalatai (1998-2004)",
abstract = "Introduction: In the past decade several multicentre, prospective, randomised trials revealed a significant progress in the therapy for chronic viral hepatitis, but limited and controversal data are available regarding the real value of the antiviral treatment in the everyday routine clinical praxis. Aim: A nation-wide retrospective analysis has been made of the antiviral therapy for patients with hepatitis B and C, who represented the entire patient population necessitating treatment in Hungary during a seven-year period. In addition, results of a prospective study for chronic hepatitis C patients were also presented. Patients and methods: A total of 220 patients with chronic hepatitis B treated with standard interferon α (112), pegylated interferon α 2a (23), or lamivudine (85) were investigated and assessed for the HBeAg seroconversion and/or undetectable HBV-DNA. Out of 2442 chronic hepatitits C patients, 333 were treated with standard interferon monotherapy, 1122 with standard interferon + ribavirin and 987 with pegilated interferon plus ribavirin combination for 6-12 months. In a prospective study, 69 patients with chronic hepatitis C were enrolled and treated with pegilated interferon α-2a plus ribavirin. The rate of sustained virological response, the predictors of outcome and the adverse effects of treatment were evaluated. Results: For HBV patients standard IFN provided 31{\%}, PEG-IFN 30{\%} and lamivudine 31-33{\%} sustained virological response rate, respectively. In chronic hepatitis C, a continuous improvement was noted in sustained virological response, from 13{\%} by interferon monotherapy, to 31{\%} by pegilated interferon plus ribavirin combination, in the nation-wide retrospective study, while even a 48{\%} sustained virological response was achieved in the prospective trial. The most important predictors of outcome were the 4-week {"}rapid{"} and the 12-week {"}early{"} virological responses, then the female sex, age, BMI and adherence. The most frequent complications of the antiviral treatment were cytopenias, haemolysis and depression, 9{\%} of patients experienced adverse effects. Conclusion: The efficacy of antiviral treatment unlike HBV infection, in chronic HCV hepatitis gradually improved in our every-day clinical praxis, but the results are far poorer than those achieved in a prospective study. To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimized, individualized dosing and novel antivirals.",
keywords = "Antiviral treatment, Chronic viral hepatitis, HBV, HCV, National survey, Prospective study",
author = "A. P{\'a}r and Istv{\'a}n Tornai and F. Szalay",
year = "2007",
month = "5",
day = "6",
doi = "10.1556/OH.2007.28114",
language = "Hungarian",
volume = "148",
pages = "819--826",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18",

}

TY - JOUR

T1 - A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998-2004)

AU - Pár, A.

AU - Tornai, István

AU - Szalay, F.

PY - 2007/5/6

Y1 - 2007/5/6

N2 - Introduction: In the past decade several multicentre, prospective, randomised trials revealed a significant progress in the therapy for chronic viral hepatitis, but limited and controversal data are available regarding the real value of the antiviral treatment in the everyday routine clinical praxis. Aim: A nation-wide retrospective analysis has been made of the antiviral therapy for patients with hepatitis B and C, who represented the entire patient population necessitating treatment in Hungary during a seven-year period. In addition, results of a prospective study for chronic hepatitis C patients were also presented. Patients and methods: A total of 220 patients with chronic hepatitis B treated with standard interferon α (112), pegylated interferon α 2a (23), or lamivudine (85) were investigated and assessed for the HBeAg seroconversion and/or undetectable HBV-DNA. Out of 2442 chronic hepatitits C patients, 333 were treated with standard interferon monotherapy, 1122 with standard interferon + ribavirin and 987 with pegilated interferon plus ribavirin combination for 6-12 months. In a prospective study, 69 patients with chronic hepatitis C were enrolled and treated with pegilated interferon α-2a plus ribavirin. The rate of sustained virological response, the predictors of outcome and the adverse effects of treatment were evaluated. Results: For HBV patients standard IFN provided 31%, PEG-IFN 30% and lamivudine 31-33% sustained virological response rate, respectively. In chronic hepatitis C, a continuous improvement was noted in sustained virological response, from 13% by interferon monotherapy, to 31% by pegilated interferon plus ribavirin combination, in the nation-wide retrospective study, while even a 48% sustained virological response was achieved in the prospective trial. The most important predictors of outcome were the 4-week "rapid" and the 12-week "early" virological responses, then the female sex, age, BMI and adherence. The most frequent complications of the antiviral treatment were cytopenias, haemolysis and depression, 9% of patients experienced adverse effects. Conclusion: The efficacy of antiviral treatment unlike HBV infection, in chronic HCV hepatitis gradually improved in our every-day clinical praxis, but the results are far poorer than those achieved in a prospective study. To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimized, individualized dosing and novel antivirals.

AB - Introduction: In the past decade several multicentre, prospective, randomised trials revealed a significant progress in the therapy for chronic viral hepatitis, but limited and controversal data are available regarding the real value of the antiviral treatment in the everyday routine clinical praxis. Aim: A nation-wide retrospective analysis has been made of the antiviral therapy for patients with hepatitis B and C, who represented the entire patient population necessitating treatment in Hungary during a seven-year period. In addition, results of a prospective study for chronic hepatitis C patients were also presented. Patients and methods: A total of 220 patients with chronic hepatitis B treated with standard interferon α (112), pegylated interferon α 2a (23), or lamivudine (85) were investigated and assessed for the HBeAg seroconversion and/or undetectable HBV-DNA. Out of 2442 chronic hepatitits C patients, 333 were treated with standard interferon monotherapy, 1122 with standard interferon + ribavirin and 987 with pegilated interferon plus ribavirin combination for 6-12 months. In a prospective study, 69 patients with chronic hepatitis C were enrolled and treated with pegilated interferon α-2a plus ribavirin. The rate of sustained virological response, the predictors of outcome and the adverse effects of treatment were evaluated. Results: For HBV patients standard IFN provided 31%, PEG-IFN 30% and lamivudine 31-33% sustained virological response rate, respectively. In chronic hepatitis C, a continuous improvement was noted in sustained virological response, from 13% by interferon monotherapy, to 31% by pegilated interferon plus ribavirin combination, in the nation-wide retrospective study, while even a 48% sustained virological response was achieved in the prospective trial. The most important predictors of outcome were the 4-week "rapid" and the 12-week "early" virological responses, then the female sex, age, BMI and adherence. The most frequent complications of the antiviral treatment were cytopenias, haemolysis and depression, 9% of patients experienced adverse effects. Conclusion: The efficacy of antiviral treatment unlike HBV infection, in chronic HCV hepatitis gradually improved in our every-day clinical praxis, but the results are far poorer than those achieved in a prospective study. To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimized, individualized dosing and novel antivirals.

KW - Antiviral treatment

KW - Chronic viral hepatitis

KW - HBV

KW - HCV

KW - National survey

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=34447260765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447260765&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.28114

DO - 10.1556/OH.2007.28114

M3 - Article

C2 - 17468063

AN - SCOPUS:34447260765

VL - 148

SP - 819

EP - 826

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18

ER -